ECSP099778A - Dosis intravenosa y oral de un inhibidor p2y12 de acción directa y reversible - Google Patents
Dosis intravenosa y oral de un inhibidor p2y12 de acción directa y reversibleInfo
- Publication number
- ECSP099778A ECSP099778A EC2009009778A ECSP099778A ECSP099778A EC SP099778 A ECSP099778 A EC SP099778A EC 2009009778 A EC2009009778 A EC 2009009778A EC SP099778 A ECSP099778 A EC SP099778A EC SP099778 A ECSP099778 A EC SP099778A
- Authority
- EC
- Ecuador
- Prior art keywords
- intravenous
- inhibitor
- direct
- oral dose
- reversible action
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Este invento brinda métodos y compuestos para una inhibición plaquetaria rápida y reversible en sujetos humanos que necesitan de la misma cuando se administran compuestos con la fórmula (I), Ya sea sola o en combinación con un segundo agente que puede ser aspirina o un agente trombolítico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91564907P | 2007-05-02 | 2007-05-02 | |
US94792107P | 2007-07-03 | 2007-07-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP099778A true ECSP099778A (es) | 2010-01-29 |
Family
ID=39587015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2009009778A ECSP099778A (es) | 2007-05-02 | 2009-12-02 | Dosis intravenosa y oral de un inhibidor p2y12 de acción directa y reversible |
Country Status (17)
Country | Link |
---|---|
US (2) | US20090048216A1 (es) |
EP (1) | EP2079464A2 (es) |
JP (1) | JP2010526101A (es) |
KR (1) | KR20100029746A (es) |
CN (1) | CN101795682A (es) |
AU (1) | AU2008247483A1 (es) |
BR (1) | BRPI0811476A2 (es) |
CA (1) | CA2686203A1 (es) |
CO (1) | CO6241104A2 (es) |
EA (1) | EA200901473A1 (es) |
EC (1) | ECSP099778A (es) |
GT (1) | GT200900284A (es) |
IL (1) | IL201834A0 (es) |
MA (1) | MA31663B1 (es) |
MX (1) | MX2009011843A (es) |
TN (1) | TN2009000451A1 (es) |
WO (1) | WO2008137753A2 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101423483B1 (ko) * | 2005-11-03 | 2014-07-28 | 포톨라 파마슈티컬스, 인코포레이티드 | 〔4-(6-할로-7-치환된-2,4-디옥소-1,4-디히드로-2h-퀴나졸린-3-일)-페닐〕-5-클로로티오펜-2-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법 |
WO2008107436A1 (en) * | 2007-03-06 | 2008-09-12 | Novartis Ag | Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions |
US20090156620A1 (en) * | 2007-05-02 | 2009-06-18 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
EP2076510A2 (en) * | 2007-05-02 | 2009-07-08 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof, and formulations thereof, for the treatment of thrombosis and trombosis related conditions |
US9427448B2 (en) * | 2009-11-11 | 2016-08-30 | The Medicines Company | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
WO2010075861A2 (en) * | 2008-12-30 | 2010-07-08 | Thrombologic Aps | Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof |
US10376532B2 (en) | 2009-11-11 | 2019-08-13 | Chiesi Farmaceutici, S.P.A. | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
EA028885B1 (ru) | 2009-11-11 | 2018-01-31 | Чиези Фармачеутичи С.П.А. | Способы лечения или предотвращения тромбоза стента и инфаркта миокарда (варианты) |
ES2548845T3 (es) * | 2009-12-23 | 2015-10-21 | Ratiopharm Gmbh | Forma de dosificación farmacéutica sólida de ticagrelor y ácido acetilsalicílico |
US20130165459A1 (en) | 2010-01-12 | 2013-06-27 | Norvartis Pharma Ag | Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof |
WO2011137459A1 (en) * | 2010-04-30 | 2011-11-03 | Portola Pharmaceuticals, Inc. | Dosage forms of elinogrel and methods of injectable administration thereof |
WO2012072743A1 (en) * | 2010-12-01 | 2012-06-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and kits for determining platelet susceptibility to activation in a patient |
US8987285B2 (en) * | 2010-12-03 | 2015-03-24 | Portola Pharmaceuticals, Inc. | Pharmaceutical compositions, dosage forms and new forms of the compound of formula (I), and methods of use thereof |
JP2020510043A (ja) | 2017-03-15 | 2020-04-02 | イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd | P2y12受容体アンタゴニストの皮下投与 |
WO2018234565A1 (en) | 2017-06-23 | 2018-12-27 | Chiesi Farmaceutici S.P.A. | METHOD FOR PREVENTING SHUNT THROMBOSIS FROM THE SYSTEMIC-PULMONARY ARTERY |
CN107462648B (zh) * | 2017-08-21 | 2019-09-27 | 盐城锦明药业有限公司 | 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6906063B2 (en) * | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
KR101423483B1 (ko) | 2005-11-03 | 2014-07-28 | 포톨라 파마슈티컬스, 인코포레이티드 | 〔4-(6-할로-7-치환된-2,4-디옥소-1,4-디히드로-2h-퀴나졸린-3-일)-페닐〕-5-클로로티오펜-2-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법 |
-
2008
- 2008-05-02 EP EP08747561A patent/EP2079464A2/en not_active Withdrawn
- 2008-05-02 KR KR1020097025059A patent/KR20100029746A/ko not_active Application Discontinuation
- 2008-05-02 BR BRPI0811476-5A2A patent/BRPI0811476A2/pt not_active IP Right Cessation
- 2008-05-02 CA CA002686203A patent/CA2686203A1/en not_active Abandoned
- 2008-05-02 MX MX2009011843A patent/MX2009011843A/es not_active Application Discontinuation
- 2008-05-02 CN CN200880023071A patent/CN101795682A/zh active Pending
- 2008-05-02 AU AU2008247483A patent/AU2008247483A1/en not_active Abandoned
- 2008-05-02 EA EA200901473A patent/EA200901473A1/ru unknown
- 2008-05-02 JP JP2010506688A patent/JP2010526101A/ja not_active Withdrawn
- 2008-05-02 US US12/114,630 patent/US20090048216A1/en not_active Abandoned
- 2008-05-02 WO PCT/US2008/062518 patent/WO2008137753A2/en active Application Filing
-
2009
- 2009-10-29 IL IL201834A patent/IL201834A0/en unknown
- 2009-10-30 GT GT200900284A patent/GT200900284A/es unknown
- 2009-10-30 TN TNP2009000451A patent/TN2009000451A1/fr unknown
- 2009-11-26 MA MA32377A patent/MA31663B1/fr unknown
- 2009-12-02 CO CO09137697A patent/CO6241104A2/es not_active Application Discontinuation
- 2009-12-02 EC EC2009009778A patent/ECSP099778A/es unknown
-
2011
- 2011-09-16 US US13/235,305 patent/US20120009172A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2079464A2 (en) | 2009-07-22 |
MX2009011843A (es) | 2010-04-22 |
US20120009172A1 (en) | 2012-01-12 |
CO6241104A2 (es) | 2011-01-20 |
TN2009000451A1 (en) | 2011-03-31 |
MA31663B1 (fr) | 2010-09-01 |
BRPI0811476A2 (pt) | 2014-11-04 |
EA200901473A1 (ru) | 2010-06-30 |
IL201834A0 (en) | 2010-06-16 |
AU2008247483A1 (en) | 2008-11-13 |
KR20100029746A (ko) | 2010-03-17 |
JP2010526101A (ja) | 2010-07-29 |
CA2686203A1 (en) | 2008-11-13 |
GT200900284A (es) | 2012-01-31 |
WO2008137753A3 (en) | 2009-02-12 |
WO2008137753A2 (en) | 2008-11-13 |
CN101795682A (zh) | 2010-08-04 |
US20090048216A1 (en) | 2009-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP099778A (es) | Dosis intravenosa y oral de un inhibidor p2y12 de acción directa y reversible | |
AR068185A1 (es) | Composiciones de tabletas de desintegracion oral de lamotrigina | |
CL2013001136A1 (es) | Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional. | |
HK1160779A1 (en) | Cdk inhibitor for the treatment of mesothelioma | |
ECSP099376A (es) | Inhibidores de la actividad de la akt | |
BR112015020466A8 (pt) | inibidores de cdc7, seus usos, e composição farmacêutica | |
NI200700320A (es) | Inhibidores de la actividad akt | |
CY1112387T1 (el) | Θεραπευτικη συνθεση περιεχουσα τουλαχιστον ενα παραγωγο της πυρρολοβενζοδιαζεπινης και φλουδαραβινη | |
CY1121865T1 (el) | Οφθαλμολογικες συνθεσεις και η χρηση τους | |
SV2009003335A (es) | Formulaciones para el cancer | |
GT200900008A (es) | Derivados novedosos de aminopiridina que tienen acción inhibidora selectiva sobre aurora a | |
AR033175A1 (es) | Usos farmaceuticos de bisfosfonatos | |
GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
CL2011000798A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
CL2011000806A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
UY35859A (es) | ?combinación farmacéutica que comprende amlodipina, losartán y rosuvastatina?. | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
MX2009004017A (es) | Usos de los compuestos carboxi-amido triazol y sus sales. | |
HN2003000063A (es) | Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades. | |
CL2013001250A1 (es) | Composicion intravenosa que contiene ibuprofeno y paracetamol combinados en dosis definidas; y uso en el tratamiento del dolor y/o inflamacion. | |
CO2017003263A2 (es) | Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer | |
CL2009001841A1 (es) | Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto. | |
CY1116672T1 (el) | Χρηση αδαπαλενης και βενζοϋλυπεροξειδιου για την μακροχρονια αντιμετωπιση της κοινης ακμης | |
CL2011000805A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion de lictus en pacientes que padecen fibrilacion auricular. | |
IT1398773B1 (it) | Sequenze oligonucleotidiche inibitrici dell'espressione della chimera ciclina d1/trop2 e loro uso in campo medico. |